- Home
- AEF vs CVRX Comparison
AEF vs CVRX Comparison
Compare AEF & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEF | CVRX |
|---|---|---|
| Founded | 1989 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.7M | 253.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEF | CVRX |
|---|---|---|
| Price | $6.87 | $9.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.17 |
| AVG Volume (30 Days) | 92.5K | ★ 232.9K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | ★ $55,969,000.00 |
| Revenue This Year | N/A | $11.49 |
| Revenue Next Year | N/A | $16.26 |
| P/E Ratio | $8.86 | ★ N/A |
| Revenue Growth | N/A | ★ 18.44 |
| 52 Week Low | $4.40 | $4.30 |
| 52 Week High | $5.53 | $18.55 |
Technical Indicators
Market Signals| Indicator | AEF | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.53 | 43.50 |
| Support Level | $6.41 | $8.82 |
| Resistance Level | $6.76 | $9.63 |
| Average True Range (ATR) | 0.08 | 0.67 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 88.24 | 34.29 |
Price Performance
Historical ComparisonAbout AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.